Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally ad­vanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.

Authors

Felix Keil

Medical Dept. Int. Med. 3, Hematology and Oncology, Hanusch-Krankenhaus, Vienna, Austria

Felix Keil , Maximilian Hartl , Gabriela Altorjai , Martin Pecherstorfer , Beate Mayrbäurl , Alexander de Vries , Andrea Berghold , Regina Riedl , Michael A. Fridrik , Thorsten Fuereder , Martin Burian , Richard Greil

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Randomized phase II study with or without induction chemotherapy combined with accelerated high dose radiotherapy and cetuximab in locally advanced unresectable HPV positive squamous cell carcinoma of the head and neck.

First Author: Signe Friesland

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.

First Author: Pol M. Specenier

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.

First Author: Erminia Massarelli

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus  docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

First Author: D. Adkins